Mortality in DATATOP: A multicenter trial in early Parkinson's disease

Annals of Neurology

Volumn 43, Issue 3, 1998, Pages 318-325

  Shoulson, ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; LEVODOPA; SELEGILINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT PLANNING;

AGED; ANTIPARKINSON AGENTS; CAUSE OF DEATH; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; SELEGILINE; VITAMIN E;

EID: 0031893241     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410430309     Document Type: Article

References (20)

1. Rajput AH, Offord KP, Beard CM, Kurland LT. Epidemiology of parkinsonism: incidence, classification and mortality. Ann Neurol 1984;16:278-282
2. Ebmeier K, Calder SA, Crawford JR, et al. Parkinson's disease in Aberdeen: survival after 3-5 years. Acta Neurol Scand 1990; 81:294-299
3. Ben-Shlomo Y, Marmot MG. Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry 1995;58:293-299
4. Tison F, Letenneur L, Djossou F, Dartigues JF. Further evidence of increased risk of mortality from Parkinson's disease. J Neurol Neurosurg Psychiatry 1996;60:592-593
5. Parkinson's Disease Research Group in the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. BMJ 1993;307:469-472
6. Lees AJ (Parkinson's Disease Research Group of the United Kingdom). Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 1995;311: 1602-1607
7. Parkinson Study Group. DATATOP: a multi-center controlled clinical trial in early Parkinson's disease. Arch Neurol 1989;46: 1052-1060
8. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1989; 321:1364-1371
9. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183
10. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Ann Neurol 1996;39:29-36
11. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects requiring levodopa. Ann Neurol 1996;39:37-45
12. Schulzer M, Mak E, Calne DB. The antiparkinsonian efficacy of deprenyl derives from transient improvement that is likely to be symptomatic. Ann Neurol 1992;32:795-798
13. Ward CD. Does selegiline delay progression of Parkinson's disease? A critical reevaluation of the DATATOP study. J Neurol Neurosurg Psychiatry 1994;57:217-220
14. National Center for Health Statistics. Vital statistics of the United States, 1991, vol 11, mortality, part A. DHHS publication no. (PHS) 96-1101. Washington, DC: Public Health Service, 1996
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
16. Cox DR. Regression models and life tables (with discussion). J R Stat Soc [B] 1972;34:187-220
17. Clayton, DG. Analysis of event history data: a review of progress and outstanding problems. Stat Med 1988;7:819-842
18. Olanow CW, Godbold JM, Koller W. Patients taking selegiline may have received more levodopa than necessary BMJ 1996; 213:702-703
19. Birkmayer W, Knoll J, Riederer P, Youdim MB. (-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease. Mod Probl Pharmacopsychiatry 1983;19:170-176
20. Birkmayer W, Knoll J, Riederer P, et al. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm 1985;64:113-127